查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1423782

全球皮膚和系統性利甚曼病市場 - 全球產業分析、規模、份額、成長、趨勢、預測 (2031) - 按藥物類別、按給藥途徑、按適應症、按分銷管道、按地區

Cutaneous and Systemic Leishmaniasis Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region:
出版日期: | 出版商: Fairfield Market Research | 英文 215 Pages | 商品交期: 2-5個工作天內

價格
簡介目錄

在 2024-2031 年預測期內，全球皮膚和系統性利甚曼病市場規模呈上升趨勢。 這種成長可歸因於推動市場擴張的幾個關鍵因素。

推動皮膚和系統性利甚曼病市場成長的關鍵因素之一是透過聯合藥物治療實現的令人印象深刻的臨床治癒率。 多種藥物的組合已被證明非常有效，有些組合可以完全治癒。 這一充滿希望的方面預計將在整個預測期內維持市場成長。

皮膚和系統性利甚曼病市場的許多利益相關者正在大力投資研發，旨在開發創新療法。 正在進行的各種藥物和治療的臨床試驗顯示出有希望的結果，並有望為皮膚和系統性利甚曼病的治療開闢新的可能性。

世界各國政府正大力投資醫療基礎設施，為市場成長做出貢獻。 此外，私人健康保險提供者提供優惠的報銷政策，允許患者選擇最適合自己需求的計劃，使治療更加容易。

由於藥物昂貴，治療皮膚和系統性利甚曼病的費用仍然相對較高，而且這些治療可能會產生嚴重的副作用。 然而，正在進行的研究和開發工作預計將在未來產生更具成本效益和更安全的治療方法。

皮膚和系統性利甚曼病市場競爭激烈，其特徵是大公司主導該行業。 市場進入者正在採取技術聯盟、經銷商協議、研發強化和產品發布等新的創新策略，以滿足不斷增長的需求並建立區域市場優勢。

本報告研究了全球皮膚和系統性利甚曼病市場，按藥物類別、給藥途徑、適應症、分銷管道、區域趨勢和市場進入提供了市場概述。我們提供以下資訊：這樣做的公司的競爭趨勢。

目錄

第 1 章執行摘要

第二章市場概述

  • 市場定義與細分
  • 市場動態
  • 價值鏈分析
  • 波特五力分析
  • 新冠肺炎 (COVID-19) 影響分析
  • 烏克蘭和俄羅斯之間衝突的影響
  • 經濟概況
  • 杵分析

第 3 章 2018-2031 年全球皮膚與系統性利甚曼病市場展望

  • 2018-2031 年全球皮膚和系統性利甚曼病市場展望（按藥物類別、價值（十億美元））
  • 2018-2031 年全球皮膚和系統性利甚曼病市場展望（按給藥途徑）、價值（十億美元）
  • 2018-2031 年全球皮膚和系統性利甚曼病市場展望（按適應症、價值（十億美元））
  • 2018-2031 年全球皮膚和系統性利甚曼病市場展望（按分銷管道）、價值（美元）
  • 2018-2031 年全球皮膚和系統性利甚曼病市場展望（按地區、價值（十億美元））

第 4 章北美皮膚與系統性利甚曼病市場展望，2018-2031

第 5 章歐洲皮膚與系統性利甚曼病市場前景，2018-2031

第 6 章亞太地區皮膚與系統性利甚曼病市場展望，2018-2031

第 7 章拉丁美洲皮膚與系統性利甚曼病市場展望，2018-2031 年

第 8 章中東和非洲皮膚和系統性利甚曼病市場展望，2018-2031 年

第九章競爭態勢

  • 藥物類別和適應症的熱圖
  • 2023 年公司市佔率分析
  • 競爭對手儀表板
  • 公司簡介
    • Gilead Sciences, Inc.
    • Profounda Pharmaceuticals
    • Knight Therapeutics Inc.
    • Janssen Global Services, LLC
    • Albert David Ltd
    • Jubilant Life Sciences Ltd.
    • Novartis AG
    • Sanofi
    • Endo Pharmaceuticals Inc
    • Bristol-Myers Squibb Company
    • United Biotech Pvt. Ltd.

第 10 章附錄

簡介目錄

The global Cutaneous and Systemic Leishmaniasis market is on an upward trajectory over the forecast period 2024-2031. This growth can be attributed to several key factors that are driving the market's expansion.

High Clinical Cure Rate with Combinational Drug Therapy

One of the pivotal factors fueling the growth of the Cutaneous and Systemic Leishmaniasis market is the impressive clinical cure rate achieved through combinational drug therapy. The use of various drug combinations has proven to be highly effective, with some combinations even resulting in complete cures. This promising aspect is expected to sustain the market's growth throughout the forecast period.

Increased Investments for Research And Development

Numerous stakeholders in the Cutaneous and Systemic Leishmaniasis market are making substantial investments in research and development efforts aimed at developing innovative treatment alternatives. Ongoing clinical trials for a wide range of drugs and therapies show promising outcomes, which are anticipated to open up new opportunities for treating cutaneous and systemic leishmaniasis.

Favorable Reimbursement Policies

Governments worldwide are significantly investing in healthcare infrastructure, contributing to the growth of the market. Additionally, private health insurance providers are offering favorable reimbursement policies, allowing patients to choose plans that best suit their needs, further facilitating access to treatment.

However, the market does face some challenges:

High Cost of Treatment and Chances Of Side Effects

The cost of treating Cutaneous and Systemic Leishmaniasis remains relatively high due to expensive drugs, and these treatments may have serious side effects. Nevertheless, ongoing research and development efforts are expected to yield more cost-effective and safer treatment options in the future.

Impact of COVID-19

The COVID-19 pandemic initially led to a decrease in demand for Cutaneous & Systemic Leishmaniasis treatment due to healthcare facilities' overwhelming focus on managing the pandemic. However, as the situation improved in 2021, demand for these treatments started to rebound.

Competitive Analysis

The Cutaneous and Systemic Leishmaniasis market is fiercely competitive and is characterized by major players dominating the industry. Market participants are embracing new and innovative strategies, including technological collaborations, distributorship agreements, increased research and development, and product launches, to meet growing demand and establish their dominance in regional markets.

Key Companies Profiled

  • Gilead Sciences, Inc.
  • Profounda Pharmaceuticals
  • Knight Therapeutics Inc.
  • Janssen Global Services, LLC
  • Albert David Ltd
  • Jubilant Life Sciences Ltd.
  • Novartis AG
  • Sanofi
  • Endo Pharmaceuticals Inc
  • Bristol-Myers Squibb Company
  • United Biotech Pvt. Ltd.

As the Cutaneous & Systemic Leishmaniasis market continues to grow and evolve, these key players are at the forefront of driving advancements in research, development, and access to treatment, ensuring a brighter future for those affected by this disease.

Cutaneous and Systemic Leishmaniasis Market Categorization

Cutaneous and Systemic Leishmaniasis Market by By Drug Class

  • Pentavalent Antimonials
  • Antifungal Drugs
  • Anti-Lesihmanial/Antimicrobial Drugs

Cutaneous and Systemic Leishmaniasis Market By Route of Administration

  • Oral
  • Injectable
  • Topical

Cutaneous and Systemic Leishmaniasis Market By Indication

  • Cutaneous Leishmaniasis
  • Mucosal Leishmaniasis
  • Visceral Leishmaniasis

Cutaneous and Systemic Leishmaniasis Market By Distribution Channel

  • Hospital Pharmacies,
  • Retail Pharmacies
  • Drug Stores
  • Online Pharmacies

Cutaneous and Systemic Leishmaniasis Market by Region

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa (MEA)

Table of Contents

1. Executive Summary

  • 1.1. Global Cutaneous and Systemic Leishmaniasis Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2023
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. Porter's Five Forces Analysis
  • 2.5. COVID-19 Impact Analysis
    • 2.5.1. Supply
    • 2.5.2. Demand
  • 2.6. Impact of Ukraine-Russia Conflict
  • 2.7. Economic Overview
    • 2.7.1. World Economic Projections
  • 2.8. PESTLE Analysis

3. Global Cutaneous and Systemic Leishmaniasis Market Outlook, 2018 - 2031

  • 3.1. Global Cutaneous and Systemic Leishmaniasis Market Outlook, by Drug Class, Value (US$ Bn), 2018 - 2031
    • 3.1.1. Key Highlights
      • 3.1.1.1. Pentavalent Antimonials
      • 3.1.1.2. Antifungal Drugs
      • 3.1.1.3. Anti-Lesihmanial/Antimicrobial Drugs
  • 3.2. Global Cutaneous and Systemic Leishmaniasis Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2031
    • 3.2.1. Key Highlights
      • 3.2.1.1. Oral
      • 3.2.1.2. Injectable
      • 3.2.1.3. Topical
  • 3.3. Global Cutaneous and Systemic Leishmaniasis Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
    • 3.3.1. Key Highlights
      • 3.3.1.1. Cutaneous Leishmaniasis
      • 3.3.1.2. Mucosal Leishmaniasis
      • 3.3.1.3. Visceral Leishmaniasis
  • 3.4. Global Cutaneous and Systemic Leishmaniasis Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 3.4.1. Key Highlights
      • 3.4.1.1. Hospital Pharmacies,
      • 3.4.1.2. Retail Pharmacies
      • 3.4.1.3. Drug Stores
      • 3.4.1.4. Online Pharmacies
  • 3.5. Global Cutaneous and Systemic Leishmaniasis Market Outlook, by Region, Value (US$ Bn), 2018 - 2031
    • 3.5.1. Key Highlights
      • 3.5.1.1. North America
      • 3.5.1.2. Europe
      • 3.5.1.3. Asia Pacific
      • 3.5.1.4. Latin America
      • 3.5.1.5. Middle East & Africa

4. North America Cutaneous and Systemic Leishmaniasis Market Outlook, 2018 - 2031

  • 4.1. North America Cutaneous and Systemic Leishmaniasis Market Outlook, by Drug Class, Value (US$ Bn), 2018 - 2031
    • 4.1.1. Key Highlights
      • 4.1.1.1. Pentavalent Antimonials
      • 4.1.1.2. Antifungal Drugs
      • 4.1.1.3. Anti-Lesihmanial/Antimicrobial Drugs
  • 4.2. North America Cutaneous and Systemic Leishmaniasis Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2031
    • 4.2.1. Key Highlights
      • 4.2.1.1. Oral
      • 4.2.1.2. Injectable
      • 4.2.1.3. Topical
  • 4.3. North America Cutaneous and Systemic Leishmaniasis Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
    • 4.3.1. Key Highlights
      • 4.3.1.1. Cutaneous Leishmaniasis
      • 4.3.1.2. Mucosal Leishmaniasis
      • 4.3.1.3. Visceral Leishmaniasis
  • 4.4. North America Cutaneous and Systemic Leishmaniasis Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 4.4.1. Key Highlights
      • 4.4.1.1. Hospital Pharmacies,
      • 4.4.1.2. Retail Pharmacies
      • 4.4.1.3. Drug Stores
      • 4.4.1.4. Online Pharmacies
    • 4.4.2. BPS Analysis/Market Attractiveness Analysis
  • 4.5. North America Cutaneous and Systemic Leishmaniasis Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 4.5.1. Key Highlights
      • 4.5.1.1. U.S. Cutaneous and Systemic Leishmaniasis Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 4.5.1.2. U.S. Cutaneous and Systemic Leishmaniasis Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 4.5.1.3. U.S. Cutaneous and Systemic Leishmaniasis Market by Indication, Value (US$ Bn), 2018 - 2031
      • 4.5.1.4. U.S. Cutaneous and Systemic Leishmaniasis Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 4.5.1.5. Canada Cutaneous and Systemic Leishmaniasis Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 4.5.1.6. Canada Cutaneous and Systemic Leishmaniasis Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 4.5.1.7. Canada Cutaneous and Systemic Leishmaniasis Market by Indication, Value (US$ Bn), 2018 - 2031
      • 4.5.1.8. Canada Cutaneous and Systemic Leishmaniasis Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 4.5.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Cutaneous and Systemic Leishmaniasis Market Outlook, 2018 - 2031

  • 5.1. Europe Cutaneous and Systemic Leishmaniasis Market Outlook, by Drug Class, Value (US$ Bn), 2018 - 2031
    • 5.1.1. Key Highlights
      • 5.1.1.1. Pentavalent Antimonials
      • 5.1.1.2. Antifungal Drugs
      • 5.1.1.3. Anti-Lesihmanial/Antimicrobial Drugs
  • 5.2. Europe Cutaneous and Systemic Leishmaniasis Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2031
    • 5.2.1. Key Highlights
      • 5.2.1.1. Oral
      • 5.2.1.2. Injectable
      • 5.2.1.3. Topical
  • 5.3. Europe Cutaneous and Systemic Leishmaniasis Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
    • 5.3.1. Key Highlights
      • 5.3.1.1. Cutaneous Leishmaniasis
      • 5.3.1.2. Mucosal Leishmaniasis
      • 5.3.1.3. Visceral Leishmaniasis
  • 5.4. Europe Cutaneous and Systemic Leishmaniasis Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 5.4.1. Key Highlights
      • 5.4.1.1. Hospital Pharmacies,
      • 5.4.1.2. Retail Pharmacies
      • 5.4.1.3. Drug Stores
      • 5.4.1.4. Online Pharmacies
    • 5.4.2. BPS Analysis/Market Attractiveness Analysis
  • 5.5. Europe Cutaneous and Systemic Leishmaniasis Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 5.5.1. Key Highlights
      • 5.5.1.1. Germany Cutaneous and Systemic Leishmaniasis Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 5.5.1.2. Germany Cutaneous and Systemic Leishmaniasis Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 5.5.1.3. Germany Cutaneous and Systemic Leishmaniasis Market by Indication, Value (US$ Bn), 2018 - 2031
      • 5.5.1.4. Germany Cutaneous and Systemic Leishmaniasis Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.5.1.5. U.K. Cutaneous and Systemic Leishmaniasis Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 5.5.1.6. U.K. Cutaneous and Systemic Leishmaniasis Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 5.5.1.7. U.K. Cutaneous and Systemic Leishmaniasis Market by Indication, Value (US$ Bn), 2018 - 2031
      • 5.5.1.8. U.K. Cutaneous and Systemic Leishmaniasis Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.5.1.9. France Cutaneous and Systemic Leishmaniasis Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 5.5.1.10. France Cutaneous and Systemic Leishmaniasis Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 5.5.1.11. France Cutaneous and Systemic Leishmaniasis Market by Indication, Value (US$ Bn), 2018 - 2031
      • 5.5.1.12. France Cutaneous and Systemic Leishmaniasis Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.5.1.13. Italy Cutaneous and Systemic Leishmaniasis Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 5.5.1.14. Italy Cutaneous and Systemic Leishmaniasis Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 5.5.1.15. Italy Cutaneous and Systemic Leishmaniasis Market by Indication, Value (US$ Bn), 2018 - 2031
      • 5.5.1.16. Italy Cutaneous and Systemic Leishmaniasis Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.5.1.17. Turkey Cutaneous and Systemic Leishmaniasis Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 5.5.1.18. Turkey Cutaneous and Systemic Leishmaniasis Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 5.5.1.19. Turkey Cutaneous and Systemic Leishmaniasis Market by Indication, Value (US$ Bn), 2018 - 2031
      • 5.5.1.20. Turkey Cutaneous and Systemic Leishmaniasis Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.5.1.21. Russia Cutaneous and Systemic Leishmaniasis Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 5.5.1.22. Russia Cutaneous and Systemic Leishmaniasis Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 5.5.1.23. Russia Cutaneous and Systemic Leishmaniasis Market by Indication, Value (US$ Bn), 2018 - 2031
      • 5.5.1.24. Russia Cutaneous and Systemic Leishmaniasis Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.5.1.25. Rest of Europe Cutaneous and Systemic Leishmaniasis Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 5.5.1.26. Rest of Europe Cutaneous and Systemic Leishmaniasis Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 5.5.1.27. Rest of Europe Cutaneous and Systemic Leishmaniasis Market by Indication, Value (US$ Bn), 2018 - 2031
      • 5.5.1.28. Rest of Europe Cutaneous and Systemic Leishmaniasis Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 5.5.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Cutaneous and Systemic Leishmaniasis Market Outlook, 2018 - 2031

  • 6.1. Asia Pacific Cutaneous and Systemic Leishmaniasis Market Outlook, by Drug Class, Value (US$ Bn), 2018 - 2031
    • 6.1.1. Key Highlights
      • 6.1.1.1. Pentavalent Antimonials
      • 6.1.1.2. Antifungal Drugs
      • 6.1.1.3. Anti-Lesihmanial/Antimicrobial Drugs
  • 6.2. Asia Pacific Cutaneous and Systemic Leishmaniasis Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2031
    • 6.2.1. Key Highlights
      • 6.2.1.1. Oral
      • 6.2.1.2. Injectable
      • 6.2.1.3. Topical
  • 6.3. Asia Pacific Cutaneous and Systemic Leishmaniasis Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
    • 6.3.1. Key Highlights
      • 6.3.1.1. Cutaneous Leishmaniasis
      • 6.3.1.2. Mucosal Leishmaniasis
      • 6.3.1.3. Visceral Leishmaniasis
  • 6.4. Asia Pacific Cutaneous and Systemic Leishmaniasis Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 6.4.1. Key Highlights
      • 6.4.1.1. Hospital Pharmacies,
      • 6.4.1.2. Retail Pharmacies
      • 6.4.1.3. Drug Stores
      • 6.4.1.4. Online Pharmacies
    • 6.4.2. BPS Analysis/Market Attractiveness Analysis
  • 6.5. Asia Pacific Cutaneous and Systemic Leishmaniasis Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 6.5.1. Key Highlights
      • 6.5.1.1. China Cutaneous and Systemic Leishmaniasis Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 6.5.1.2. China Cutaneous and Systemic Leishmaniasis Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 6.5.1.3. China Cutaneous and Systemic Leishmaniasis Market by Indication, Value (US$ Bn), 2018 - 2031
      • 6.5.1.4. China Cutaneous and Systemic Leishmaniasis Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 6.5.1.5. Japan Cutaneous and Systemic Leishmaniasis Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 6.5.1.6. Japan Cutaneous and Systemic Leishmaniasis Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 6.5.1.7. Japan Cutaneous and Systemic Leishmaniasis Market by Indication, Value (US$ Bn), 2018 - 2031
      • 6.5.1.8. Japan Cutaneous and Systemic Leishmaniasis Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 6.5.1.9. South Korea Cutaneous and Systemic Leishmaniasis Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 6.5.1.10. South Korea Cutaneous and Systemic Leishmaniasis Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 6.5.1.11. South Korea Cutaneous and Systemic Leishmaniasis Market by Indication, Value (US$ Bn), 2018 - 2031
      • 6.5.1.12. South Korea Cutaneous and Systemic Leishmaniasis Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 6.5.1.13. India Cutaneous and Systemic Leishmaniasis Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 6.5.1.14. India Cutaneous and Systemic Leishmaniasis Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 6.5.1.15. India Cutaneous and Systemic Leishmaniasis Market by Indication, Value (US$ Bn), 2018 - 2031
      • 6.5.1.16. India Cutaneous and Systemic Leishmaniasis Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 6.5.1.17. Southeast Asia Cutaneous and Systemic Leishmaniasis Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 6.5.1.18. Southeast Asia Cutaneous and Systemic Leishmaniasis Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 6.5.1.19. Southeast Asia Cutaneous and Systemic Leishmaniasis Market by Indication, Value (US$ Bn), 2018 - 2031
      • 6.5.1.20. Southeast Asia Cutaneous and Systemic Leishmaniasis Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 6.5.1.21. Rest of Asia Pacific Cutaneous and Systemic Leishmaniasis Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 6.5.1.22. Rest of Asia Pacific Cutaneous and Systemic Leishmaniasis Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 6.5.1.23. Rest of Asia Pacific Cutaneous and Systemic Leishmaniasis Market by Indication, Value (US$ Bn), 2018 - 2031
      • 6.5.1.24. Rest of Asia Pacific Cutaneous and Systemic Leishmaniasis Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 6.5.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Cutaneous and Systemic Leishmaniasis Market Outlook, 2018 - 2031

  • 7.1. Latin America Cutaneous and Systemic Leishmaniasis Market Outlook, by Drug Class, Value (US$ Bn), 2018 - 2031
    • 7.1.1. Key Highlights
      • 7.1.1.1. Pentavalent Antimonials
      • 7.1.1.2. Antifungal Drugs
      • 7.1.1.3. Anti-Lesihmanial/Antimicrobial Drugs
  • 7.2. Latin America Cutaneous and Systemic Leishmaniasis Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2031
    • 7.2.1. Key Highlights
      • 7.2.1.1. Oral
      • 7.2.1.2. Injectable
      • 7.2.1.3. Topical
  • 7.3. Latin America Cutaneous and Systemic Leishmaniasis Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
    • 7.3.1. Key Highlights
      • 7.3.1.1. Cutaneous Leishmaniasis
      • 7.3.1.2. Mucosal Leishmaniasis
      • 7.3.1.3. Visceral Leishmaniasis
  • 7.4. Latin America Cutaneous and Systemic Leishmaniasis Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 7.4.1. Key Highlights
      • 7.4.1.1. Hospital Pharmacies,
      • 7.4.1.2. Retail Pharmacies
      • 7.4.1.3. Drug Stores
      • 7.4.1.4. Online Pharmacies
    • 7.4.2. BPS Analysis/Market Attractiveness Analysis
  • 7.5. Latin America Cutaneous and Systemic Leishmaniasis Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 7.5.1. Key Highlights
      • 7.5.1.1. Brazil Cutaneous and Systemic Leishmaniasis Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 7.5.1.2. Brazil Cutaneous and Systemic Leishmaniasis Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 7.5.1.3. Brazil Cutaneous and Systemic Leishmaniasis Market by Indication, Value (US$ Bn), 2018 - 2031
      • 7.5.1.4. Brazil Cutaneous and Systemic Leishmaniasis Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 7.5.1.5. Mexico Cutaneous and Systemic Leishmaniasis Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 7.5.1.6. Mexico Cutaneous and Systemic Leishmaniasis Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 7.5.1.7. Mexico Cutaneous and Systemic Leishmaniasis Market by Indication, Value (US$ Bn), 2018 - 2031
      • 7.5.1.8. Mexico Cutaneous and Systemic Leishmaniasis Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 7.5.1.9. Argentina Cutaneous and Systemic Leishmaniasis Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 7.5.1.10. Argentina Cutaneous and Systemic Leishmaniasis Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 7.5.1.11. Argentina Cutaneous and Systemic Leishmaniasis Market by Indication, Value (US$ Bn), 2018 - 2031
      • 7.5.1.12. Argentina Cutaneous and Systemic Leishmaniasis Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 7.5.1.13. Rest of Latin America Cutaneous and Systemic Leishmaniasis Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 7.5.1.14. Rest of Latin America Cutaneous and Systemic Leishmaniasis Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 7.5.1.15. Rest of Latin America Cutaneous and Systemic Leishmaniasis Market by Indication, Value (US$ Bn), 2018 - 2031
      • 7.5.1.16. Rest of Latin America Cutaneous and Systemic Leishmaniasis Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 7.5.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Cutaneous and Systemic Leishmaniasis Market Outlook, 2018 - 2031

  • 8.1. Middle East & Africa Cutaneous and Systemic Leishmaniasis Market Outlook, by Drug Class, Value (US$ Bn), 2018 - 2031
    • 8.1.1. Key Highlights
      • 8.1.1.1. Pentavalent Antimonials
      • 8.1.1.2. Antifungal Drugs
      • 8.1.1.3. Anti-Lesihmanial/Antimicrobial Drugs
  • 8.2. Middle East & Africa Cutaneous and Systemic Leishmaniasis Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2031
    • 8.2.1. Key Highlights
      • 8.2.1.1. Oral
      • 8.2.1.2. Injectable
      • 8.2.1.3. Topical
  • 8.3. Middle East & Africa Cutaneous and Systemic Leishmaniasis Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
    • 8.3.1. Key Highlights
      • 8.3.1.1. Cutaneous Leishmaniasis
      • 8.3.1.2. Mucosal Leishmaniasis
      • 8.3.1.3. Visceral Leishmaniasis
  • 8.4. Middle East & Africa Cutaneous and Systemic Leishmaniasis Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 8.4.1. Key Highlights
      • 8.4.1.1. Hospital Pharmacies,
      • 8.4.1.2. Retail Pharmacies
      • 8.4.1.3. Drug Stores
      • 8.4.1.4. Online Pharmacies
    • 8.4.2. BPS Analysis/Market Attractiveness Analysis
  • 8.5. Middle East & Africa Cutaneous and Systemic Leishmaniasis Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 8.5.1. Key Highlights
      • 8.5.1.1. GCC Cutaneous and Systemic Leishmaniasis Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 8.5.1.2. GCC Cutaneous and Systemic Leishmaniasis Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 8.5.1.3. GCC Cutaneous and Systemic Leishmaniasis Market by Indication, Value (US$ Bn), 2018 - 2031
      • 8.5.1.4. GCC Cutaneous and Systemic Leishmaniasis Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 8.5.1.5. South Africa Cutaneous and Systemic Leishmaniasis Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 8.5.1.6. South Africa Cutaneous and Systemic Leishmaniasis Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 8.5.1.7. South Africa Cutaneous and Systemic Leishmaniasis Market by Indication, Value (US$ Bn), 2018 - 2031
      • 8.5.1.8. South Africa Cutaneous and Systemic Leishmaniasis Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 8.5.1.9. Egypt Cutaneous and Systemic Leishmaniasis Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 8.5.1.10. Egypt Cutaneous and Systemic Leishmaniasis Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 8.5.1.11. Egypt Cutaneous and Systemic Leishmaniasis Market by Indication, Value (US$ Bn), 2018 - 2031
      • 8.5.1.12. Egypt Cutaneous and Systemic Leishmaniasis Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 8.5.1.13. Nigeria Cutaneous and Systemic Leishmaniasis Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 8.5.1.14. Nigeria Cutaneous and Systemic Leishmaniasis Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 8.5.1.15. Nigeria Cutaneous and Systemic Leishmaniasis Market by Indication, Value (US$ Bn), 2018 - 2031
      • 8.5.1.16. Nigeria Cutaneous and Systemic Leishmaniasis Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 8.5.1.17. Rest of Middle East & Africa Cutaneous and Systemic Leishmaniasis Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 8.5.1.18. Rest of Middle East & Africa Cutaneous and Systemic Leishmaniasis Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 8.5.1.19. Rest of Middle East & Africa Cutaneous and Systemic Leishmaniasis Market by Indication, Value (US$ Bn), 2018 - 2031
      • 8.5.1.20. Rest of Middle East & Africa Cutaneous and Systemic Leishmaniasis Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 8.5.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. Drug Class vs Indication Heatmap
  • 9.2. Company Market Share Analysis, 2023
  • 9.3. Competitive Dashboard
  • 9.4. Company Profiles
    • 9.4.1. Gilead Sciences, Inc.
      • 9.4.1.1. Company Overview
      • 9.4.1.2. Product Portfolio
      • 9.4.1.3. Financial Overview
      • 9.4.1.4. Business Strategies and Development
    • 9.4.2. Profounda Pharmaceuticals
      • 9.4.2.1. Company Overview
      • 9.4.2.2. Product Portfolio
      • 9.4.2.3. Financial Overview
      • 9.4.2.4. Business Strategies and Development
    • 9.4.3. Knight Therapeutics Inc.
      • 9.4.3.1. Company Overview
      • 9.4.3.2. Product Portfolio
      • 9.4.3.3. Financial Overview
      • 9.4.3.4. Business Strategies and Development
    • 9.4.4. Janssen Global Services, LLC
      • 9.4.4.1. Company Overview
      • 9.4.4.2. Product Portfolio
      • 9.4.4.3. Financial Overview
      • 9.4.4.4. Business Strategies and Development
    • 9.4.5. Albert David Ltd
      • 9.4.5.1. Company Overview
      • 9.4.5.2. Product Portfolio
      • 9.4.5.3. Financial Overview
      • 9.4.5.4. Business Strategies and Development
    • 9.4.6. Jubilant Life Sciences Ltd.
      • 9.4.6.1. Company Overview
      • 9.4.6.2. Product Portfolio
      • 9.4.6.3. Financial Overview
      • 9.4.6.4. Business Strategies and Development
    • 9.4.7. Novartis AG
      • 9.4.7.1. Company Overview
      • 9.4.7.2. Product Portfolio
      • 9.4.7.3. Financial Overview
      • 9.4.7.4. Business Strategies and Development
    • 9.4.8. Sanofi
      • 9.4.8.1. Company Overview
      • 9.4.8.2. Product Portfolio
      • 9.4.8.3. Financial Overview
      • 9.4.8.4. Business Strategies and Development
    • 9.4.9. Endo Pharmaceuticals Inc
      • 9.4.9.1. Company Overview
      • 9.4.9.2. Product Portfolio
      • 9.4.9.3. Financial Overview
      • 9.4.9.4. Business Strategies and Development
    • 9.4.10. Bristol-Myers Squibb Company
      • 9.4.10.1. Company Overview
      • 9.4.10.2. Product Portfolio
      • 9.4.10.3. Financial Overview
      • 9.4.10.4. Business Strategies and Development
    • 9.4.11. United Biotech Pvt. Ltd.
      • 9.4.11.1. Company Overview
      • 9.4.11.2. Product Portfolio
      • 9.4.11.3. Financial Overview
      • 9.4.11.4. Business Strategies and Development

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations